Collagen Solutions plc

Equities

COS

GB00B94T6Y14

Delayed London S.E. Other stock markets 10:05:02 16/11/2020 pm IST			5-day change	1st Jan Change
6.625 ^GBX	-.--%		-.--%	+94.85%

2020	Australia shares set to snap three-day losing streak; NZ up	RE
2020	Rosen's Diversified Inc. completed the acquisition of remaining 81.3% stake in Collagen Solutions plc from a group of shareholders.	CI

Stewart White to Step Down as Chief Scientific Officer and Leave the Board of Collagen Solutions plc

April 24, 2017 at 11:30 am IST

Collagen Sol PLC announced Dr. Stewart White will step down from the role of Chief Scientific Officer and leave the board of the company to pursue other opportunities. This change will be effective from 30 June 2017 to ensure a smooth transition. After this time he will remain in a consultancy role and continue to participate as a member of the Scientific Advisory Board (SAB).

Latest news about Collagen Solutions plc

Australia shares set to snap three-day losing streak; NZ up	23/20/23	RE
Rosen's Diversified Inc. completed the acquisition of remaining 81.3% stake in Collagen Solutions plc from a group of shareholders.	19/20/19	CI
Rosen's Diversified Inc. reached an agreement to acquire remaining 81.3% stake in Collagen Solutions plc from a group of shareholders for £23.6 million.	27/20/27	CI
Collagen Solutions plc Announces Unaudited Consolidated Earnings Results for the Year Ended 31 March 2020	31/20/31	CI
Collagen Solutions plc Provides Sales Guidance for the First Quarter of 2021	31/20/31	CI
Collagen Solutions Plc Supply Agreement with NovaBone Products	07/20/07	CI
Collagen Solutions Plc Completes £0.5 million Investment in the Glasgow Facility	15/20/15	CI
Collagen Solutions Updates on Strategic Review and Formal Sale Process	18/20/18	CI
Collagen Solutions plc Provides Revenue Guidance for the Year Ended March 31, 2020	23/20/23	CI
Collagen Solutions Seeks Strategic Review	16/20/16	CI
Collagen Solutions plc Provides Earnings Guidance for the Ending March 31, 2020	18/20/18	CI
Devro : Sausage-skin maker Devro says China plant operating at normal capacity	04/20/04	RE
Collagen Solutions plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended 30 September 2019	03/19/03	CI
Collagen Solutions plc Announces Directorate Change	13/19/13	CI
Collagen Solutions plc Provides Revenue Guidance for the First Half Ended September 30, 2019	22/19/22	CI
Collagen Solutions plc Announces Directorate Change	09/19/09	CI
Collagen Solutions plc Reports Audited Consolidated Earnings Results for the Year Ended 31 March 2019	09/19/09	CI
Collagen Solutions plc Announces Appointment of Wade Rosen as Non-Executive Director	06/19/06	CI
Collagen Solutions plc Provides Revenue Guidance for the Full Year of 2019	09/19/09	CI
An undisclosed buyer acquired an unknown minority stake in Jellagen Ltd from Collagen Solutions plc for £0.22 million.	20/19/20	CI
PT Rajawali Medika Enters into Licensing Agreement with Collagen Solutions Plc	01/19/01	CI
Collagen Solutions plc Enters into New Agreement with Olaregen Therapeutix Inc. to Manufacture and Produce Excellagen	15/19/15	CI
Collagen Solutions plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2018	04/18/04	CI
Collagen Solutions plc Announces Amendments to its 2017 Bond Subscription Agreement	05/18/05	CI
Collagen Solutions plc Provides an Update on Trading for the Six Months to 30 September 2018	23/18/23	CI

Chart Collagen Solutions plc

Duration

Period

More charts

Company Profile

Collagen Solutions plc is a holding company. The Company is engaged in the business of supply, development and manufacture of medical grade collagen components and biomaterials. The Company's products and services are utilized in the research, diagnostics, medical devices and regenerative medicine markets. The Company's main products include Collagen and tissue biomaterials. The Company's product range includes raw tissue supply, including pericardium, which is used in heart valves and dural patches, various strengths of soluble and acid soluble collagen, acid swollen gels, freeze-dried powders, collagen sheets and fibrous collagen. The Company also manufactures Excellagen, a collagen gel used in wound care and cell therapy fields. Its services include product development and contract manufacturing. It offers a range of bovine spongiform encephalopathy (BSE)-free bovine biomaterials to meet customer specifications, including bone, cartilage and tendon, and veins and blood vessels.

Sector

More about the company